Cargando…

Hyperthyroidism with concurrent FMS-like tyrosine kinase 3-internal tandem duplication-positive acute promyelocytic leukemia: A case report and review of the literature

Neutropenia is a common side-effect in hyperthyroid patients with long-term use of antithyroid drugs. This may be caused by drug-induced immune dysfunction or increased thyroxine hematologic toxicity, which usually returns to normal after medication is discontinued or the hyperthyroidism becomes wel...

Descripción completa

Detalles Bibliográficos
Autores principales:	JIANG, YAJIAN, HU, KEYUE, XIE, WANZHUO, ZHENG, GAOFENG, SUN, JIE, ZHENG, YANLONG, HUANG, HE
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2014
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3881699/ https://www.ncbi.nlm.nih.gov/pubmed/24396459 http://dx.doi.org/10.3892/ol.2013.1721

Ejemplares similares

Sorafenib-induced Thyroiditis in FMS-like Tyrosine Kinase 3-internal Tandem Duplication-mutated Acute Myeloid Leukemia
por: Sun, Jie, et al.
Publicado: (2016)

Therapy-related acute promyelocytic leukemia with FMS-like tyrosine kinase 3-internal tandem duplication mutation in solitary bone plasmacytoma: A case report
por: Hong, Li-Li, et al.
Publicado: (2020)

Fms-like tyrosine kinase 3-internal tandem duplications epigenetically activates checkpoint kinase 1 in acute myeloid leukemia cells
por: Zhang, Yudong, et al.
Publicado: (2021)

FMS-related tyrosine kinase 3 internal tandem duplication (FLT3-ITD): a villain among others
por: de Arruda, Vanessa Y.N., et al.
Publicado: (2017)

Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms
por: Ruvolo, Peter P., et al.
Publicado: (2017)

Prognostic Significance of Fms-Like Tyrosine Kinase 3 Internal Tandem Duplication Mutation in Non-Transplant Adult Patients with Acute Myeloblastic Leukemia: A Systematic Review and Meta-Analysis
por: Rinaldi, Ikhwan, et al.
Publicado: (2020)

Clinical implications of combination therapy with quizartinib and craniospinal irradiation for refractory acute myeloid leukemia positive for FMS‐like tyrosine kinase 3‐internal tandem duplication with central nervous system involvement
por: Suga, Makiko, et al.
Publicado: (2022)

Integrin alphavbeta3 enhances β-catenin signaling in acute myeloid leukemia harboring Fms-like tyrosine kinase-3 internal tandem duplication mutations: implications for microenvironment influence on sorafenib sensitivity
por: Yi, Hai, et al.
Publicado: (2016)

ITDetect: a method to detect internal tandem duplication of FMS-like tyrosine kinase (FLT3) from next-generation sequencing data with high sensitivity and clinical application
por: Lee, Sungyoung, et al.
Publicado: (2023)

Hypertriglyceridemia in Newly Diagnosed Acute Promyelocytic Leukemia
por: Sun, Jianai, et al.
Publicado: (2020)

Detection of nucleophosmin and FMS-like tyrosine kinase-3 gene mutations in acute myeloid leukemia
por: Pazhakh, Vahid, et al.
Publicado: (2011)

Serum soluble FMS-like tyrosine kinase-1 in ectopic pregnancy
por: Selvarajan, Sathya, et al.
Publicado: (2019)

Soluble fms-Like Tyrosine Kinase 1 Localization in Renal Biopsies of CKD
por: Zsengellér, Zsuzsanna K., et al.
Publicado: (2019)

Peptides Targeting Fms-Related Tyrosine Kinase-4 Activate the Function of Natural Killer Cells in Acute Myeloid Leukemia
por: Park, Soojin, et al.
Publicado: (2021)

FMS-Like Tyrosine Kinase 3 Inhibitors in the Treatment of Acute Myeloid Leukemia: An Update on the Emerging Evidence and Safety Profile
por: Garciaz, Sylvain, et al.
Publicado: (2023)

Soluble fms‐like tyrosine kinase‐1‐enriched exosomes suppress the growth of small cell lung cancer by inhibiting endothelial cell migration
por: Hao, Dexun, et al.
Publicado: (2019)

AXL receptor tyrosine kinase: a possible therapeutic target in acute promyelocytic leukemia
por: Fatima, Mariam, et al.
Publicado: (2021)

Regulation of expression level of fms-like tyrosine kinase-4 is related to osteoclast differentiation
por: Zhu, Yi, et al.
Publicado: (2015)

Fms-like tyrosine kinase 3 is a regulator of the cardiac side population in mice
por: Della Verde, Giacomo, et al.
Publicado: (2021)

Soluble FMS-Like Tyrosine Kinase-1: Role in placenta accreta spectrum disorder
por: Lumbanraja, Sarma, et al.
Publicado: (2022)

The Endothelial Glycocalyx as a Target of Excess Soluble Fms-like Tyrosine Kinase-1
por: Schulz, Annika, et al.
Publicado: (2023)

Heat shock protein 90 inhibitors overcome the resistance to Fms-like tyrosine kinase 3 inhibitors in acute myeloid leukemia
por: Katayama, Kazuhiro, et al.
Publicado: (2018)

An aggressive form of non-Hodgkin's lymphoma with pleural and abdominal chylous effusions: A case report and review of the literature
por: JIANG, YAJIAN, et al.
Publicado: (2013)

FMS-like tyrosine kinase 3 is required for dendritic cell development in peripheral lymphoid tissues
por: Waskow, Claudia, et al.
Publicado: (2008)

Fms-Like Tyrosine Kinase 3 Ligand Controls Formation of Regulatory T Cells in Autoimmune Arthritis
por: Svensson, Mattias N. D., et al.
Publicado: (2013)

Soluble Fms-Like Tyrosine Kinase-1 Alters Cellular Metabolism and Mitochondrial Bioenergetics in Preeclampsia
por: Sánchez-Aranguren, Lissette C., et al.
Publicado: (2018)

Soluble Fms-Like Tyrosine Kinase-1 Is A Marker of Endothelial Dysfunction During Sepsis
por: Greco, Marilena, et al.
Publicado: (2018)

FMS‐like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer
por: Hasegawa, Hiroko, et al.
Publicado: (2020)

FMS-Related Tyrosine Kinase 3 Ligand Promotes Radioresistance in Esophageal Squamous Cell Carcinoma
por: Zhu, Zuoquan, et al.
Publicado: (2021)

High fms-like tyrosine kinase-3 (FLT3) receptor surface expression predicts poor outcome in FLT3 internal tandem duplication (ITD) negative patients in adult acute myeloid leukaemia: a prospective pilot study from India
por: Sharawat, Surender Kumar, et al.
Publicado: (2016)

How acute myeloid leukemia (AML) escapes from FMS-related tyrosine kinase 3 (FLT3) inhibitors? Still an overrated complication?
por: Perrone, Salvatore, et al.
Publicado: (2023)

Dinucleotide repeat polymorphism in Fms-like tyrosine kinase-1 (Flt-1) gene is not associated with preeclampsia
por: Kim, Shin-Young, et al.
Publicado: (2008)

Variability in mRNA expression of fms-like tyrosine kinase-1 variants in normal and preeclamptic placenta
por: Surmon, Laura, et al.
Publicado: (2014)

FMS-Like Tyrosine Kinase 3 Ligand Treatment Does Not Ameliorate Experimental Rapidly Progressive Glomerulonephritis
por: Ghali, Joanna R., et al.
Publicado: (2015)

The VEGF Inhibitor Soluble Fms-like Tyrosine Kinase 1 Does Not Promote AKI-to-CKD Transition
por: van Aanhold, Cleo C. L., et al.
Publicado: (2022)

Histone deacetylase inhibitors modulate hormesis in leukemic cells with mutant FMS-like tyrosine kinase-3
por: Zeyn, Yanira, et al.
Publicado: (2023)

Promyelocytic Blast Crisis of Chronic Myeloid Leukemia in a Patient Undergoing Therapy with a Tyrosine Kinase Inhibitor
por: Parsi, Meghana, et al.
Publicado: (2020)

Vernodalol mediates antitumor effects in acute promyelocytic leukemia cells
por: Wu, Wenjun, et al.
Publicado: (2018)

The incidence and prognostic effect of Fms-like tyrosine kinase 3 gene internal tandem and nucleolar phosphoprotein 1 genes in acute myeloid leukaemia: A PRISMA-compliant systematic review and meta-analysis
por: Liu, Heping, et al.
Publicado: (2020)

Levels of soluble fms-like tyrosine kinase one in first trimester and outcomes of pregnancy: a systematic review
por: Jacobs, Marni, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_3ibpgv1po2qleevo3n4rrn4t25